Skip to main content

Lunai Bioworks Inc.

corporate_fare Company Profile

Lunai Bioworks Inc.

LNAI·NASDAQ·Life Sciences·CIK 0001527728

Lunai Bioworks Inc. is an AI-driven biotechnology company focused on precision medicine, biomarker discovery, and therapeutic development for central nervous system (CNS) disorders, biodefense, and other serious diseases with unmet medical need. As of June 30, 2026, the company operated principally through two operating subsidiaries: Renovaro Biosciences and BioSymetrics. A third wholly owned subsidiary, Lunai Bioworks IP, Inc., holds intellectual property, including the N2B intranasal drug delivery platform, acquired in the May 2026 Neurobridge acquisition. BioSymetrics refers to BioSymetrics Inc. and its wholly owned subsidiary BioSymetrics Corp., which were acquired on April 8, 2025. During the quarter ended September 30, 2025, GEDi Cube B.V., acquired on February 13, 2024, filed for bankruptcy and ceased operations. Following GEDi Cube's bankruptcy and deconsolidation, Lunai Bioworks Inc. continued its AI-driven precision medicine and biomarker discovery strategy through BioSymetrics. BioSymetrics' existing AI and machine-learning platform provided capabilities that overlapped with GEDi Cube's cancer diagnostics and biomarker discovery objectives, while also supporting therapeutic development, central nervous system disorders, and biodefense. BioSymetrics continued pursuing cancer-related diagnostic and biomarker opportunities and expanded research and business development into additional therapeutic areas. The company's consolidated operations consist principally of Renovaro Biosciences' cell and gene therapy programs and BioSymetrics' AI-driven biotechnology platform. Lunai Bioworks Inc. combines multimodal data analytics with experimental biology to generate predictive insights to accelerate research and development and improve the efficiency of therapeutic and chemical countermeasure discovery.

Lunai Bioworks Inc. (NASDAQ:LNAI) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 31 items for LNAI at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-23, rated 9/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 17 rated 8 or above. Recent SEC coverage for LNAI spans 8-K, 10-K, 10-Q, 8-K/A.

Recent high-impact activity:

  • Lunai Bioworks to Voluntarily Delist From Nasdaq After Equity Failure
  • Lunai Bioworks to Voluntarily Delist From Nasdaq; CFO and a Director Resign
  • Lunai Bioworks 10-K: Less Than One Month of Cash, Going Concern Warning, Nasdaq Equity Deficit
  • Lunai Bioworks Requests Nasdaq Trading Suspension Amid Alleged Short-Selling Abuses
  • Lunai Bioworks Inks Exclusive Tanaist Deal to Validate Parkinson's Subtypes

Financial Snapshot

Fiscal year ended June 30, 2026
Revenue
$51.99K
Net Income
-$3.56M
Diluted EPS
-$1.06
Op. Cash Flow
-$5.29M
Free Cash Flow
-$5.29M
Operating Income
-$8.7M
Cash & Equivalents
$1.71M
Debt / Equity
0.00×
Net Margin
-68.52×
Shares Outstanding
4.62M sh
Source: 10-K · filed 2026-10-13 · accession 0001731122-26-001339

Short Interest & Short Volume

1.00 days to cover

FINRA reported short interest of 19,381 shares in LNAI as of the October 30, 2026 settlement, a 83.4% decrease from the prior period — about 1.0 days to cover at its recent average daily volume.

Short interest (bi-monthly positions)19,381 shares as of October 30, 2026
Change vs prior period▼ 83.4%
Days to cover1.00 at avg daily volume of 1,205,445

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with L →

No longer listed

LNAI (Lunai Bioworks Inc.) is no longer listed on a major US exchange, so Wiseek no longer shows market data for this symbol. It last appeared on NASDAQ. The filings and coverage below remain available as an archive.

feed LNAI - Latest Insights

LNAI
Oct 23, 2026, 2:21 AM EDT
Source: Seeking Alpha
Importance Score:
9
LNAI
Oct 22, 2026, 9:38 PM EDT
Filing Type: 8-K
Importance Score:
9
LNAI
Oct 13, 2026, 4:55 PM EDT
Filing Type: 10-K
Importance Score:
9
LNAI
Oct 09, 2026, 2:00 PM EDT
Filing Type: 8-K
Importance Score:
8
LNAI
Sep 22, 2026, 9:20 AM EDT
Source: PR Newswire
Importance Score:
7
LNAI
Aug 04, 2026, 3:28 PM EDT
Source: PR Newswire
Importance Score:
7
LNAI
Aug 04, 2026, 9:20 AM EDT
Source: PR Newswire
Importance Score:
8
LNAI
Jun 17, 2026, 4:33 PM EDT
Source: Wiseek News
Importance Score:
9
LNAI
Jun 17, 2026, 4:32 PM EDT
Filing Type: 8-K
Importance Score:
8
LNAI
Jun 16, 2026, 4:03 PM EDT
Source: Wiseek News
Importance Score:
8
LNAI
Jun 16, 2026, 4:00 PM EDT
Filing Type: 8-K
Importance Score:
8
LNAI
May 20, 2026, 9:15 AM EDT
Filing Type: 8-K
Importance Score:
8
LNAI
May 20, 2026, 9:15 AM EDT
Source: PR Newswire
Importance Score:
7
LNAI
May 15, 2026, 4:53 PM EDT
Source: Wiseek News
Importance Score:
8
LNAI
May 15, 2026, 4:46 PM EDT
Filing Type: 10-Q
Importance Score:
9
LNAI
May 13, 2026, 6:36 PM EDT
Source: Reuters
Importance Score:
8
LNAI
May 13, 2026, 4:45 PM EDT
Filing Type: 8-K
Importance Score:
8
LNAI
May 11, 2026, 5:30 PM EDT
Filing Type: 8-K/A
Importance Score:
9
LNAI
May 01, 2026, 5:23 PM EDT
Source: Wiseek News
Importance Score:
9
LNAI
May 01, 2026, 5:18 PM EDT
Filing Type: DEFR14A
Importance Score:
9
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets